{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:21:51Z","timestamp":1787678511617,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hemoglobin disorders such as thalassemia major have created an economic burden on the health care system. Iron chelation therapy (ICT) is the most expensive cost component in patients with thalassemia. ICT was administered to reduce the toxic effects of iron overload. This study aims to compare the costs of iron chelators as monotherapy in patients with thalassemia major in Indonesia, specifically in Cipto Faculty of Medicine, Universit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a retrospective analytical observational study. Data were collected from the thalassemia registry from 2016 to 2019. Patients\u2019 age, gender, type of thalassemia, and type of iron chelation were recorded. Complications and total annual costs were evaluated. All thalassemia patients aged \u22652 years who were only receiving monotherapy ICT and had no history of therapy switching were eligible. We excluded subjects who moved out to other facilities or lost to follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>From a total of 256 subjects, 249 subjects were included. The median age is 28 years old. Both sexes were represented equally. As many as 96.8% of subjects have thalassemia beta. Deferiprone was the most common iron chelator used (86.7%). Complications were observed in the subjects based on 4-year data collection; most of them were cardiomyopathy, diabetes mellitus, delayed puberty, and malnutrition (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.422; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.867; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.004; and <jats:italic toggle=\"yes\">P<\/jats:italic>=0.125, respectively). Deferiprone had a lower mean annual cost of USD 3581 than deferasirox, which had a cost of USD 6004.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cardiomyopathy, diabetes mellitus, delayed puberty, and malnutrition were the most common complications found in the study. This study showed that deferiprone should be taken as consideration as a drug of choice to treat iron overload in thalassemia provided by Indonesian national health insurance which is less costly despite the probability of complications found after the treatment was given. Further investigations are required to evaluate contributing factors of complications in thalassemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002894","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:09:22Z","timestamp":1717477762000},"page":"e402-e405","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia"],"prefix":"10.1097","volume":"46","author":[{"given":"Teny Tjitra","family":"Sari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pustika Amalia","family":"Wahidiyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi Dhyani","family":"Rahmartani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Diah","family":"Iskandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isyanaditta Agung","family":"Putri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in \u03b2-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12098-017-2325-1","article-title":"Thalassemia minor and major: current management","volume":"84","author":"Choudhry","year":"2017","journal-title":"Indian J Pediatr"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/03630269.2021.2023565","article-title":"Thalassemia in Indonesia","volume":"46","author":"Wahidiyat","year":"2022","journal-title":"Hemoglobin"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.hoc.2019.01.003","article-title":"Beta thalassemia: monitoring and new treatment approaches","volume":"33","author":"Khandros","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12913-022-07663-6","article-title":"Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study","volume":"22","author":"Alshamsi","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/voxs.12544","article-title":"An insight into Indonesian current thalassaemia care and challenges","volume":"15","author":"Wahidiyat","year":"2020","journal-title":"ISBT Sci Ser"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"e0211942","DOI":"10.1371\/journal.pone.0211942","article-title":"Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox","volume":"14","author":"Olivieri","year":"2019","journal-title":"PLoS One"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm11010015","article-title":"Quality of life and burden of disease in Italian patients with transfusion-dependent beta-thalassemia","volume":"11","author":"Tedone","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"6573497","DOI":"10.1155\/2019\/6573497","article-title":"Elevated prevalence of abnormal glucose metabolism and other endocrine disorders in patients with thalassemia major: a meta-analysis","volume":"2019","author":"He","year":"2019","journal-title":"BioMed Res Int"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13052-021-01116-2","article-title":"Detection of endocrine disorders in young children with multi-transfused thalassemia major","volume":"47","author":"Mahmoud","year":"2021","journal-title":"Ital J Pediatr"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.12.003","article-title":"Systematic literature review of the burden of disease and treatment for transfusion-dependent \u03b2-thalassemia","volume":"42","author":"Betts","year":"2020","journal-title":"Clin Ther"},{"key":"R14-20250804","first-page":"180","article-title":"Nutritional intake, sun exposure and vitamin D level in childrens with thalassemia major","volume":"142","author":"Herawati","year":"2020","journal-title":"World Sci News"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4082\/kjfm.19.0066","article-title":"Malnutrition, its attributes, and impact on quality of life: an epidemiological study among \u03b2-thalassemia major children","volume":"42","author":"Biswas","year":"2021","journal-title":"Korean J Fam Med"},{"key":"R16-20250804","first-page":"262","article-title":"The assessment of nutritional status of children with thalassemia major with body mass index","volume":"11","author":"Amin Sheikh","year":"2017","journal-title":"Pak J Med Heal Sci"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40261-017-0496-1","article-title":"Cost-utility analysis of three iron chelators used in monotherapy for the treatment of chronic iron overload in \u03b2-thalassaemia major patients: an Italian perspective","volume":"37","author":"Pepe","year":"2017","journal-title":"Clin Drug Investig"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-012-0008-2","article-title":"Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload","volume":"32","author":"Karnon","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"suppl 2","key":"R19-20250804","doi-asserted-by":"crossref","first-page":"s128","DOI":"10.5530\/jyp.2018.2s.26","article-title":"Cost-effectiveness analysis of deferiprone and deferasirox on thalassemia major patients in Tangerang District Hospital, Indonesia","volume":"10","author":"Chairunnisa","year":"2018","journal-title":"J Young Pharm"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.hemonc.2017.05.022","article-title":"Thalassemia major: Transplantation or transfusion and chelation","volume":"10","author":"Mohamed","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R21-20250804","first-page":"624","article-title":"Pediatric Hematology and Oncology","volume":"31","author":"Manal Ibrahim","year":"2014","journal-title":"Predictors of Non-Adherence to Follow-up Visits and Deferasirox Chelation Therapy Among Jordanian Adolescents with Thalassemia Major"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:57Z","timestamp":1754337897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002894","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"2023-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}